Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioplastics01:27

Bioplastics

Bioplastics derived from microbial processes present a sustainable alternative to conventional petroleum-based plastics. Among these, polyhydroxyalkanoates (PHAs), particularly polyhydroxybutyrates (PHBs), have emerged as prominent candidates due to their biodegradability and biocompatibility. These polymers are synthesized by a variety of bacteria, such as Cupriavidus necator and Pseudomonas putida, which naturally accumulate PHAs as intracellular carbon and energy reserves, especially under...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents.

The American journal of cardiology·2009
Same author

A histological "fly-through" of a diseased coronary artery.

Circulation. Cardiovascular imaging·2009
Same author

Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.

JACC. Cardiovascular interventions·2009
Same author

The history of EuroPCR... and why a new journal?

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009
Same author

Treatment of de novo bifurcation lesions: comparison of Sirolimus- and Paclitaxel-eluting stents.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009
Same author

A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2009
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

Fully biodegradable coronary stents : progress to date.

Steve Ramcharitar1, Patrick W Serruys

  • 1Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|October 3, 2008
PubMed
Summary
This summary is machine-generated.

Biodegradable stents (BDS) offer advantages over metallic stents, including reduced thrombosis and improved imaging. While challenges remain in balancing degradation and strength, recent trials show significant progress in BDS technology.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Experiment Videos

Last Updated: Jun 29, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Area of Science:

  • Cardiovascular Research
  • Biomaterials Science
  • Medical Device Engineering

Background:

  • Metallic drug-eluting stents have limitations, driving interest in biodegradable stents (BDS).
  • BDS offer benefits like eliminating foreign material, avoiding 'full metal jackets,' and enabling non-invasive cardiac imaging (MRI, CT).
  • Current BDS face challenges in balancing biocompatibility, degradation kinetics for mechanical support, and inflammation control.

Purpose of the Study:

  • To review the progress and challenges in the development of biodegradable stents (BDS).
  • To compare different biodegradable materials and designs, including polymers and metals.
  • To highlight key clinical trial findings and future directions in BDS technology.

Main Methods:

  • Review of clinical trials and pre-clinical studies on biodegradable stents.
  • Analysis of material properties, degradation profiles, and biocompatibility of various BDS prototypes.
  • Evaluation of clinical outcomes, including restenosis, major adverse cardiac events (MACE), and device performance.

Main Results:

  • The ABSORB trial (everolimus-eluting poly-L-lactide stent) showed comparable restenosis to metallic stents with low MACE (3.3% at 12 months).
  • The REVA stent (polytyrosine) is being evaluated for acute recoil issues with a novel locking mechanism.
  • Magnesium stents (Biotronik) showed high MACE (26.7% at 12 months) in the PROGRESS-AMS trial, while iron stents remain pre-clinical.

Conclusions:

  • Significant progress has been made in biodegradable stent technology, with polymer-based stents showing promising clinical results.
  • Achieving the optimal balance of mechanical support, biocompatibility, and controlled degradation remains a key challenge.
  • Further research and development are needed to overcome limitations and optimize biodegradable stent designs for widespread clinical adoption.